Think tank predicts life science sector role to grow as EU struggles to stay innovative
The life science sector will have a central role in a comprehensive revision of the EU’s industry policy, but a new presidency of the European Council could slow down the process, warns a Think Tank Europa representative.
by peter thomsen, eu correspondent for watch medier, translated by daniel pedersen
BRUSSELS – An increasing need to become independent in the healthcare area alongside ambitions to retain innovation in Europe will advantage the pharmaceutical industry as new framework conditions are outlined in Brussels, assesses Senior Fellow at Think Tank Europa Ditte Maria Brasso Sørensen.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo CEO spies new pricing model in EU
For subscribers
Pharma industry keeps wary eye on huge EU policy revision
For subscribers
